The "KING" ~867~Number 1 STOCKCALLER IN PENNYSTOCKS!!!

[TRADE-O-PUSS]

GM KING & 867 COURT...

$GMUI rocking steadily to .20 and beyond...

[iancnyc]

$BWMG HAS MULTIPLE QRT PROFITS, HUGE REVS, SUPER TIGHT FLOAT!

***float only 64.73 million
***21.74 million held by insiders
***outstanding 84.76 million
***8k reducing authorized shares!

$BWMG ***$247k in profits last quarter! REAL COMPANY, REAL PRODUCTS, REAL 64M FLOAT, REAL $1M+ IN REVS, REAL $247K IN PROFITS JUST LAST QUARTER!
_____________________________________________________________

***On track to do over $3mil in revs this year!
Over $1m in assets and $148k cash in the bank!
_____________________________________________________________

IMO This is not your typical pump and dump or quick flip that pinky land is filled with. This is a rising Star that if anyone does alittle DD can see that. Just as GEQU did when it hit over a million revs in just a quarter they climbed as high as .05 and still bounce between .02 and .03 today.

From my phone call with them, they have no plan for dilution or toxic lenders, the authorized share reduction proves that. They only have 350k in past convertible debit that can be converted at the holders discretion, but they are a private party with interest in the companies growth, not the typical vulture capitalist or toxic lender. BWMG is not a news driven company and they don't work for the share price to sell shares. They are confident that this coming 10k is going to be a good one too!

The 10k is a few weeks away, and this is your last chance to get in under a penny! This is a mid to long play. This one takes patience!
As the word spreads and new investors come on board this will slowly climb and then when the 10k hits, it is blast off time!
_____________________________________________________________

Brownie’s has an excellent working relationship with both U.S. Submarines, Inc. and its subsidiary Triton Submarines, LLC and a number of other submersible manufacturers.

Triton Submarine LLC is a subdiary of U.S. Submarines, Inc

https://www.google.com/maps/@27.6352189,-80.5126267,3a,75y,175.39h,90t/data=!3m6!1e1!3m4!1sdJ9sr9qm_vpYIJRSwV8laA!2e0!7i13312!8i6656!6m1!1e1

http://tritonsubs.com/

https://www.facebook.com/tritonsubs/

Triton Submarines
4 hrs • Edited •
Sir David Attenborough says he was "fantastically privileged" to use a Triton submersible to film & explore the Great Barrier Reef (nearly 60 years after his first dive).
Well Sir, here at Triton, we are "fantastically flattered".
Taken from the front page of the London Sunday Times.
?#?TeamTriton? ?#?Thankful? ?#?Attenborough? ?#?GreatBarrierReef?

http://tritonsubs.com/about/team/
_____________________________________________________________


Net revenues and accounts receivable – related parties – The Company sells products to Brownie’s Southport Divers, Inc., Brownie’s Palm Beach Divers, and Brownie’s Yacht Toys, owned by the brother of the Company’s Chief Executive Officer.

_____________________________________________________________

pictures ~ https://www.google.com/search?q=Brownie%E2%80%99s+Southport+Divers,+Inc&rlz=1C1ASRM_enUS591US591&espv=2&biw=1920&bih=955&source=lnms&tbm=isch&sa=X&ved=0ahUKEwilhNOdqafJAhVI6WMKHeN6D-MQ_AUICCgD

http://www.yachtdiver.com/news-sea-doo-seascooter-rs-series.shtml
http://www.browniesmarinegroup.com/pdf/Triton/US_Submarines_BWMG.pdf

they do life jackets as well ~ http://www.browniesmarinegroup.com/mass-murder-on-the-mediterranean-sea-calls-for-more-private-initiatives/

http://www.nauticexpo.com/prod/brownies-marine-group/product-33872-439315.html

http://www.amazon.com/Viking-PV9509-BMG-SOLAS-2010-Life/dp/B0099RR2T2

http://www.viking-life.com/viking.nsf/public/Products-fetchtradeingitemdata.html?opendocument&listing=Lifejackets
_____________________________________________________________

Intellectual Property Rights which currently holds ten patents. The IPR of Brownie’s is also a party to numerous license agreements covering new technology it has developed.
also nice to see that company cares about people ~~>

Brownie's Marine Group Donates 85 BMG-SOLAS 2010 Lifejackets To MOAS | http://t.co/B2THEwWXlg #MOAS #SavingLives #DoWhatYouCan

— Dawn Zinn (@dellenzinn) September 24, 2014

_____________________________________________________________

Market cap still only 635,728 at .0075 - BIG ROOM HERE

BWMG Security Details
Share Structure
Market Value1 $635,728 a/o Nov 20, 2015
Outstanding Shares 84,763,702 a/o Nov 02, 2015

_____________________________________________________________

Check out the last Q http://ih.advfn.com/p.php?pid=nmona&article=69120796
Website: http://www.browniesmarinegroup.com
Phone: [phone]
Email: [e-mail]
_____________________________________________________________

[$Pistol Pete$]

$PMCB Scientists have created insulin-producing cells that could replace injections

Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.

The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.

PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.

Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.

The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.

“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.

Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.

“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.

The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.

These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.

Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.

It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.

—

Learn more here http://austrianova.com/healthcare/

[EL CHAPO]

Stock to watch for February 9th till next year. $GMUI. Remember who said it first ;)

[Warchest]

Stocks to Watch for February 9, 2016 $APOL $AUY $GOOG $JUNO $RIC $ZAGG after-hours movers $CSAL $ARIA $MPEL $UEPS

[Warchest]

GMUI ~ tomorrow .14 close ....

[Warchest]

PKGM ~ 2@.0129

[Warchest]

PKGM cracked .01 ~

[Warchest]

PKGM can it break .01 ~

[Warchest]

[EL CHAPO]

$GMUI is on its way to .50+. Mark this!!! Better buy
I told you first

[Warchest]

GMUI .12 on ask now !!!

[Warchest]

GMUI closes .11 today ~ IMO

[Warchest]

GMUI ~~~>> 1@.103 ~ 25K block will be gone soon ~

[Warchest]

upgrades $KGC $DLTR $BGFV $OMAM $GLOB $STJ $ACC $SXT $ULTI $ZAGG $BECN $MRVL $AMED $CSCO $OA $LB $SUPN $ATHN $ESS $SCG

Morning Watch list
$APOL (Pick of the Day!)
$CTRL (Short of the Day!)
$TVIX
$EGO
$KGC
$AG
$LSG
$SGMO
$GALE

[$Pistol Pete$]

$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial



January 25, 2016

SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.

In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.

The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.

The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.

In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.

PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]

[EL CHAPO]

The KING is Excited for the week ahead!! $$$$$$

[$Pistol Pete$]

$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers

Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.

Abdominal Cancers

According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:

Colorectal: 132,000

Liver: 62,000

Pancreatic: 49,000

Ovarian: 22,000

To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.

PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.

PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.

Breast Cancer

PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.

In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.

Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.

The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.

[Warchest]

So I was walking thru an alley to get to the next street over in the big city of Portland when a homeless man calls out to me "hey guy can you give me a few bucks" and he started explaining to me how he has no place to live how he doesn't eat regularly and how he drinks to stay warm. So me being a problem solver the cogs in my head are turning and this guy is starting to lay it on thick. So I pull out my checkbook write a check for 500 dollars. And hand it to him. He was speechless, I kept walking. Got around the corner and called the check in stolen. He will have 3 meals and a warm place to sleep for a few yrs to come now anyway problem solved Bahahaha

[EL CHAPO]

I promise whoever gets in $GMUI will be very happy next "Friday" one week from today!!! ;). All I can say.
The "king" has spoken!!!
$GMUI end of story. Wanna see major profits? Not saying it again. Set your buy order now for Monday morning mine are already in!!!

[EL CHAPO]

NOTICE--IMPORTANT--PLEASE READ if you like to make money:
"Warchest" at 7:48am today called a .10 close on $GMUI which was the high of the day as well. Coincidence? I think not. In the same sentence he stated ".13" close this coming Tuesday....and then $$$$$$. 20 cents plus by end of week.....I'm not missing this. Buying Monday. Heavily. Watch this week for $GMUI to make its way back to .50+ cents. I will be holding my $GMUI shares until .50+. Good luck!!!

$GMUI

[TarHeelTrades]

$GTHP fellas give it a lookie, have a great weekend

[Warchest]

will own that float ... ~~ train ride

[TRADE-O-PUSS]

no eod weekend whacks for beer money!!! STRENGTH!!!

$GMUI

[Warchest]

should be close to .16 by end of next week IMo then !!! screw them .000 pos tickers

[TRADE-O-PUSS]

she is stomping through to .20s!!!

[Warchest]

GMUI !! .103 up lots more to go next week ..

[Warchest]

GMUI !! ALL THAT GLITTERS is GOLD ………CNBC , Obama coming on TV in a little bit to BRAG about huge JOB growth
1% growth , 3 million new job

[EL CHAPO]

"867 the KING" likes $GMUI!!!! I'm hearing massive run this week coming!!! Huge money

[Warchest]

GMUI .098 ~~~~ .20 coming soon 5mil float

[Warchest]

GMUI .09 now !!!

[blackshirej]

COBI

News just dropped!
http://ih.advfn.com/p.php?pid=nmona&article=70267078&symbol=COBI

[Warchest]

Morning ~

[Warchest]

GMUI .10 close today ~ by next tues .13 ~ then $$$$$

[Warchest]

Hey mikey moneybucket ~ you are not going to play games with us anymore we know what your up to .... and we are one step ahead of your BS (WINK)

[EL CHAPO]

I know what I'm buying tomorrow ;).... Hehehehhehehe
Very excited.

[Warchest]

GMUI 25K at .087 going maybe today !!

[Warchest]

NWPN 176% gains

[Warchest]

NWPN 144% gains

[Warchest]

NWPN 120 % !!!!

[TarHeelTrades]

$ICNV going to turn some heads $0.0032

[threewheeler]

SPCL diluter BMAK dumped his last and moved off L2 altogether, ask smacking kicking in high gear here .0002s

[Warchest]

NWPN 100% gains ~ 1@.005

[Warchest]

nWpn 68% GAINS 2@.005

[Warchest]

ask should get hit out here shorty .... (wink)

[TRADE-O-PUSS]

grabbed a few

[Warchest]

GMUI ~~ http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120308249

[Warchest]

OTC markets suck ~

[Warchest]

Pre-market movers $VHC $GLUU $SEDG $SVA $TTWO $CDNS $VRNG $VIAB $NXPI $ING
$GLUU, $WFT, $SVA, $ING, $HMY, $UNIS, $PETX,

[INTHEKNOW1]

PGEI.0008 UP 60% FAST WED EOD, ANNOUNCED ZERO DILUTION AND FLOAT OF 120M GONNA FLY!